News

The non-exclusive distribution agreement is for a one-year period and covers the New York Tri-state area. The initial order is for approximately $70,000 retail value, the company said.

Certification was granted by the Federal Agency for Medicines and Health Products (FAMHP) in Belgium. The Mont-St-Guibert production facilities are used in the manufacture and testing of Cardio3

Under the agreement, the companies will conduct a feasibility study to develop a dry powder inhaler (DPI) dosage form for a RespiVert compound. SkyePharma chief executive officer Peter

The Chozn platform enables faster, simpler selection and scale-up of high-producing clones for the production of recombinant protein drugs. The new platform consists of the cGMP-produced and tested

The test, which uses a proprietary chemistry that eliminates the need for nucleic-acid extraction, is performed on liquid or unformed human stool samples and detects the toxin B

As per the agreement, Lonza will produce commercial material at its microbial manufacturing facility in Kourim, Czech Republic. With the agreement, Lonza will be able to seek approval

The new solution provides the block randomization methodology, to assign newly enrolled patients to a treatment group, in addition to the allocation methodology. Balance offers sponsors built-in simulation

Statistically significant progression free survival benefit was achieved in 214-patient randomized controlled Phase II trial. The 404 trial evaluated the efficacy and safety of two doses of TH-302,

FAMPYRA received Health Canada approval for the symptomatic improvement of walking in adult MS patients with walking disability. The approval of FAMPYRA was based on the results of